Ultragenyx in $30M Upfront Payment to Arcturus in Pact Expansion

June 19, 2019, 4:36 PM

Ultragenyx Pharmaceutical and Arcturus Therapeutics have expanded their collaboration to discover and develop mRNA, DNA & siRNA therapeutics for up to 12 rare disease targets.

  • In connection with amendment to license pact, Ultragenyx made $6 million cash upfront payment to Arcturus and Ultragenyx is purchasing 2.4 million shares of Arcturus’ stock at $10/share
  • Ultragenyx has an option to buy another 600,000 shares of Arcturus’ stock at $16/share
  • Ultragenyx will become Arcturus’ largest shareholder with General Counsel Karah Parschauer joining Arcturus’ board & CEO Emil Kakkis joining as an Arcturus board observer
  • Investigational New Drug application for mRNA therapeutic program, UX053, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.